Back to results
US 2020/0392076 A1Published application
Antiviral agents for drug-resistant influenza a
AssigneesThomas Jefferson University, Ramot at Tel-Aviv University Ltd.
InventorsNir Ben-Tal, Roger S. Armen, Laurence C. Eisenlor, Jitendra Belani, Michael Miller, Inbar Fish, Ori Kalid
Life of this patent
Estimating the term…
Abstract
An effective therapeutic agent for the M2 channel comprising sulfonylamide or oxabicyclo structures effective for treating amantadine-resistant influenza A infections, and methods of treating amantadine-resistant influenza A infections through adminstration of the same.
Claims21
A compound of Formula 1:
- wherein X1, X2, X3, X4, X6, X7, and X8 are independently a hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
- and
- X5 is a CH2OH, hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
- or a pharmaceutically acceptable salt thereof.
1 more element
A compound of Formula 2:
- wherein X1, X2, X4, X5, X6, X7, X8, X9, X10, X11, and X12 hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
- and
- X3 is a nitro, nitrile, carboxyl, ester, sulfonamide, methylsulfone, hydroxyl, methoxy, ethoxy, hydrogen, alkyl, alkenyl, alkynyl, cycloalkyl or aryl, F, Cl, or Br;
- or a pharmaceutially acceptable salt thereof, with the proviso that X1 and X5 are not both methyl when X2, X4, X6, X7, X8, X9, X10, and X11 are hydrogen;
- X12 is a methoxy or Cl, and X3 is a nitro.
2 more elements
-14. (canceled)
Dependencies are inferred from the claim text.